Law360, New York (October 23, 2009, 2:37 PM ET) -- EU antitrust regulators have cleared Merck & Co.’s proposed $41.1 billion acquisition of Schering-Plough Corp., a move that will make it the second-largest prescription drug company in the world.
The European Commission said Friday that the proposed deal would not “significantly impede effective competition” in Europe.
The New Jersey-based companies already have a working relationship based on a joint venture they entered into a few years ago for marketing and studying the cholesterol drugs Vytorin and Zetia. The union of Merck and Schering would form one...
EU Blesses Merck's $41B Schering-Plough Deal
To view the full article, take a free trial now.
